Adults with painful imaging-confirmed knee osteoarthritis continuing paracetamol
Studied preparation
Defined oral CBD added to continued paracetamol versus matched placebo add-on
Route
oral
Primary outcome
WOMAC pain subscale change at eight weeks
Study scope
One parallel randomized cohort; completer count and randomized count remain distinct
Reported finding · selected human evidence
The selected trial did not show an additional knee-pain benefit from CBD compared with placebo added to continued paracetamol.
One selected formulation and eight-week cohort; this is not a synthesis of every CBD or cannabis-oil pain study.
1 distinct randomized cohort in this source set. Rat osteoarthritis evidence is a different system and not an additional human efficacy trial.
Reported effects and harms
Estimates retain their original comparator, units and 95% confidence interval (CI). Different measures are not pooled. Study regimens identify the research; they are not treatment instructions.
86 randomized; 84 received treatment; 58 completed the trial.
The reported between-group primary outcome difference was small and its interval included zero.
Contrast
Measure
Estimate
95% CI
CBD add-on minus placebo add-on
Mean difference in pain-score reduction at eight weeks
0.1 WOMAC pain points (0–10)
−0.8 to 1.0 WOMAC pain points (0–10)
Harms reported
135 adverse events with CBD and 105 with placebo are event totals, not counts of affected people.
Interpretation limits
Single center, substantial discontinuation and imputed intention-to-treat analysis. Trigal Pharma funded the study; authors report no role in its conduct or reporting.
Source depth
Primary full text: primary outcome, statistical analysis and adverse events.
No laboratory context selected in this pilot source set.
Source checks and notices
The selected PubMed records were checked 2026-11-08 UTC. No other notice signals were returned for these records at that check; missing metadata signals do not prove that no notice exists. This monitor checks citation relations, not every full-text change, and never rewrites a finding automatically.
Research context, not a recommendation for a medicine, dose or retail product. Findings for the studied preparation do not establish equivalence to products in the catalog.